Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 779 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05514899RecruitingPhase 2
Cannabidiol and THC study for gut health and brain inflammation in HIV
This Phase 2 study tests whether cannabidiol (CBD) and tetrahydrocannabinol (THC) change the gut microbiome and brain-related inflammation in people with HIV. It may help researchers understand new ways to reduce inflammation, but you would need strict cannabis and CBD/THC avoidance during the study.
San Diego, CaliforniaAges 21–70 - NCT05419024RecruitingPhase 2
Imaging and biopsy during a planned HIV treatment pause
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Bethesda, MarylandAges 18–100 - NCT05433948Enrolling by invitation
Testing ways to diagnose mild brain changes in liver disease
This study looks at how well simple brain tests can detect early (minimal) thinking changes related to liver cirrhosis. It may help doctors spot these changes sooner and diagnose the condition more accurately.
EsbjergAges 18–90 - NCT05369052RecruitingPhase 3
New antibiotic for moderate or severe diabetic foot infections
This Phase 3 trial tests a new medicine (contezolid acefosamil, and contezolid) to treat moderate or severe diabetic foot infections. It compares the new treatment to linezolid to see which works better and is safer for adults.
Corona, CaliforniaAges 18 years+ - NCT05345847Recruiting
Steroid-sparing treatment for immune hepatitis during cancer immunotherapy
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
Calgary, AlbertaAges 18 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT05248919Enrolling by invitation
Study treatment for hepatitis C that did not work before
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
Karachi, SindhAges 18–100 - NCT05141058RecruitingPhase 1
T cell therapy to help prevent COVID-19 after transplant
This Phase 1 trial tests a donated immune-cell treatment (T cells) to help immunocompromised people fight or resist COVID-19 after they recently received a bone marrow or stem cell transplant. It aims to see if the treatment is safe and if it helps the body respond better to the virus.
Washington D.C., District of ColumbiaAges 2–80 - NCT05045482RecruitingPhase 1
Study drug in people with cirrhosis from blocked bile flow
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
Indianapolis, IndianaAges 18–80 - NCT05018481RecruitingEarly Phase 1
Study for moderate alcoholic hepatitis after heavy drinking
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
Cleveland, OhioAges 21–65 - NCT05027711RecruitingPhase 2
MRI-guided precise radiation for liver metastases
This Phase 2 trial tests an MRI-guided, highly targeted radiation treatment (SBRT) for tumors that have spread to the liver. It may help shrink 1–3 liver metastases while using imaging to better guide treatment.
HeidelbergAges 18 years+ - NCT04941274RecruitingPhase 1/Phase 2
Abemaciclib for Kaposi sarcoma in people with or without HIV
This Phase 1/2 study tests the medicine abemaciclib to shrink Kaposi sarcoma (KS) lesions and control the disease. It includes both people with HIV and people without HIV, and may help when KS has not responded well to prior treatment or when certain KS stages are present.
Bethesda, MarylandAges 18–99 - NCT04914611Recruiting
Real-world study of chronic hepatitis B care in Australia
This study looks at people who have long-term hepatitis B and how they receive care in Australia. It may help improve understanding of what’s working in real life for patients like you.
Sydney, New South WalesAges 18 years+ - NCT04883905Recruiting
Registry study for people with acute hepatic porphyria
This study is a registry (a list) of people diagnosed with acute hepatic porphyria. It helps researchers learn about the condition and track health information over time; it doesn’t test a new drug in the way treatment trials do.
Birmingham, AlabamaAges 12 years+ - NCT04493385Recruiting
Heart transplant after a hepatitis C–positive donor
This trial follows people who receive a heart from a donor whose blood tested positive for hepatitis C. It also includes people getting a heart transplant again, and it aims to learn about outcomes and safety for these specific transplant situations.
Dallas, TexasAges 18 years+ - NCT04484025Enrolling by invitationPhase 2
Study of an oral drug for hospitalized COVID-19 patients
This trial tests an oral drug called SPI-1005 for people hospitalized with moderate COVID-19. The drug may help reduce inflammation and protect the lungs, and the study will compare it to a placebo (a pill with no active medicine) to see if it helps people recover.
New Haven, ConnecticutAges 18 years+ - NCT04271488RecruitingPhase 1
Study drug levels in people with mild or moderate liver problems
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
Hakata, FukuokaAges 20–79 - NCT04230356RecruitingPhase 2
Viral immune T-cells for viral infections after stem cell transplant
This Phase 2 study tests donor-made immune T-cells that specifically target viruses to treat or prevent viral infections after a stem cell transplant. It may help your body control dangerous viruses like adenovirus, CMV, EBV, and BK virus, while checking safety with different timing of the treatment.
Cincinnati, OhioAges Any age - NCT04234139Enrolling by invitation
Study of severe alcoholic hepatitis patients before early liver transplant
This study follows people with severe alcoholic hepatitis who are being considered for an early liver transplant before they’ve been sober for 6 months. It aims to better understand this group’s situation and ethics/safety as early transplantation plans are made.
Baltimore, MarylandAges 18 years+ - NCT04088370Recruiting
Testing blood immune cell response in alcohol-related liver disease
This study looks at how immune cells in the blood respond in people with alcoholic hepatitis and in people who drink heavily (with no known liver disease). It may help researchers understand why liver inflammation happens after heavy alcohol use.
Cleveland, OhioAges 21–65 - NCT04096014Recruiting
Protein supplement at night to prevent repeat brain episodes
This study tests whether taking extra protein in the late evening or early morning can lower the chance of being readmitted for hepatic encephalopathy, a brain problem that can happen with liver disease. It may help by supporting safer nutrition and reducing the risk of another hospitalization.
Cleveland, OhioAges 18–75 - NCT04106518Recruiting
Genetics study of alcohol-related liver disease and cirrhosis
This study looks at genetic differences in people with alcohol-related liver illness, including a recent jaundice episode (alcoholic hepatitis). By following people over time, it may help doctors better predict illness and understand why some people develop worse liver problems.
AngersAges 18 years+ - NCT03826433RecruitingPhase 1
Study stem cell treatment for worsening hepatitis B cirrhosis
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
Changsha, HunanAges 18–60
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 779 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.